TY - JOUR
AB - Treatment-resistant hypertension is associated with an increased risk of cardiovascular morbidity and mortality. Treatment recommendations include a combination of at least three antihypertensive drug classes, including a diuretic. Although there is limited evidence to support selection of add-on therapy, mineralocorticoid receptor antagonists (e.g. spironolactone and eplerenone) can effectively reduce blood pressure when added to standard combination therapy, and should be considered as fourth-line treatment options.
TI - Consider mineralocorticoid receptor antagonists as add-on therapy in treatment-resistant hypertension
JF - Drugs & Therapy Perspectives
DO - 10.1007/s40267-015-0229-6
DA - 2015-07-21
UR - https://www.deepdyve.com/lp/springer-journals/consider-mineralocorticoid-receptor-antagonists-as-add-on-therapy-in-HgqxNov506
SP - 345
EP - 349
VL - 31
IS - 10
DP - DeepDyve
ER -